Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04547855
Status:
UNKNOWN
Last Update Posted:
2020-09-14
First Post:
2020-09-11
Brief Title:
Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Sponsor:
Yonggao Mou
Organization:
Sun Yat-sen University
Study Overview
Official Title:
A Phase II Study of Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently6 cycles of Temozolomide adjuvant chemotherapy after concurrent radiotherapy and Temozolomide chemotherapySTUPP regimenfor newly diagnosed postoperative GBM can increase the 2-year and 5-year overall survival rates of patients to 265 and 98 respectively However most patients are still unable to avoid tumor recurrence and deathAnlotinib is an efficient multi-target tyrosine kinase inhibitor TKI that effectively block the migration and proliferation of endothelial cells and reduce tumor microvascular density by targeting VEGFRs FGFRs PDGFRs It has been proved to be safe and effective in advanced lung cancerincluding NSCLCSCLCafter second-line standard chemotherapy failureand advanced soft tissue sarcoma after anthracycline-containing chemotherapy failureHere we prepared to evaluate whether the combination of dose-dense Temozolomide and Anlotinib can preferably improved survival of the first recurrent or progressive GBM after STUPP regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None